U.S. Rep. Earl Blumenauer wrote to DEA Administrator Anne Milgram Feb. 8 for further details on the review process, including when the agency might publish its draft rule on the scheduling of cannabis.
Nearly two months after U.S. Rep. Earl Blumenauer, D-Ore., received a reply from the U.S. Drug Enforcement Administration (DEA) in response to he and 30 of his colleagues urging the agency to end federal cannabis prohibition, the congressman submitted yet another letter to the DEA demanding answers on the agency’s ongoing cannabis scheduling review.
In a Feb. 8 letter addressed to DEA Administrator Anne Milgram, Blumenauer reiterated that while moving cannabis to Schedule III under the Controlled Substances Act, as the U.S. Department of Health and Human Services (HHS) recommended in August, “would be an important step in the right direction,” rescheduling “is not sufficient to correct the wrongs of federal prohibition or to meaningfully address the federal-state gap on cannabis policy.”
Blumenauer requested that the DEA respond to the following questions:
- What is DEA’s planned deadline to publish its draft rule on the scheduling of marijuana for public comment?
- What is the standard timeline for DEA’s drug scheduling reviews?
- On what date did DEA begin its review following receipt of HHS’s findings and recommendation on marijuana scheduling?
- How is DEA ensuring the agency’s review incorporates the status of marijuana under state laws and regulations in its scheduling decision?
- How will DEA proactively communicate developments and receive feedback from congressional partners as the review proceeds?
Read More
2024-02-08 - DEA Response Letter on Scheduling Review Process - EB Only
